Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Atricure Inc. Stock

Price
Target price
€35.20

€35.20

2.330%
0.8
2.330%
€44.76

€44.76

 
Buy 6 Sell 0
Buy 6
Sell 0
30.07.26 / Frankfurt WKN: A0ES9W / Symbol: ATRC / Name: AtriCure / Stock / Healthcare Equipment & Supplies / Small Cap /
Latest predictions
€43.94
28.07.26
2.29%
buy
05.04.26
41.94%
buy
03.04.26
41.94%
buy
€46.43
18.02.26
30.66%
buy
€45.59
18.02.26
30.66%
buy
€40.85
16.12.25
1.73%
buy
Show more
Best running prediction
-
05.04.26
41.94%
buy
Your prediction
Pros and Cons of Atricure Inc. in the next few years
Wizard

Atricure Inc. Stock

Atricure Inc. gained 2.330% today.
Atricure Inc. is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a target price of 44 € there is a positive potential of 25.0% for Atricure Inc. compared to the current price of 35.2 €.
What does AtriCure do?

Pros and Cons of Atricure Inc. in the next few years

Pros
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Atricure Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Atricure Inc. 2.330% 22.222% 41.935% -43.226% 3.529% -43.226% -51.111%
Lantheus Holdings Inc 0.920% -3.947% -9.877% 39.269% 53.147% 9.802% -
Natera Inc 6.410% 0.473% -1.599% 88.629% 18.731% 446.495% 147.513%
Orasure Tech -1.160% 4.268% -11.856% 18.750% 66.019% -18.182% -63.648%

Comments

Prediction Buy
Perf. (%) 2.29%
Target price 43.940
Change
Ends at 28.07.27

AtriCure (ATRC) was given a new $50.00 price target by UBS Group AG. They now have a "buy" rating on the stock.
Ratings data for ATRC provided by MarketBeat
Show more

UBS Group AG 
0
Report Share
28.07.26

AtriCure (ATRC) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Ratings data for ATRC provided by MarketBeat
Show more

StockNews.com 
0
Report Share
05.04.26 Buy 41.94%

AtriCure (ATRC) was upgraded by Freedom Capital to "strong-buy".
Ratings data for ATRC provided by MarketBeat
Show more

Freedom Capital 
0
Report Share
03.04.26 Buy 41.94%
Show more
Not a member yet? Sign up for free!

News

AtriCure Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png
AtriCure Q2 Earnings Call Highlights

Key Points

MarketBeat 
0 24.07.26
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth OutlookPhoto, wide shot, wide-angle lens, Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook

AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and

MarketBeat 
0 12.05.26
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?Photo, wide shot, wide-angle lens, Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?

This medical device innovator for cardiac surgery reported an insider sale amid a year of negative total returns.

Doraiswamy Vinayak, Chief Scientific Officer of AtriCure (NASDAQ:ATRC), reported the

TheMotleyFool 
0 18.03.26